{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:44:10Z","timestamp":1792608250888,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001719.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"reference-count":100,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001719.pub4","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T00:26:25Z","timestamp":1352420785000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bromperidol decanoate (depot) for schizophrenia"],"prefix":"10.1002","volume":"2012","author":[{"given":"Marianna","family":"Purgato","sequence":"first","affiliation":[{"name":"University of Verona; Department of Public Health and Community Medicine, Section of Psychiatry; Policlinico \"G.B.Rossi\" Pzz.le L.A. Scuro, 10 Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health, Sir Colin Campbell Building, University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,14]]},"reference":[{"key":"10.1002\/14651858.CD001719.pub4-BIB0001|cit1","unstructured":"McLaren S Cookson JC Silverstone JT A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic schizophrenia Annual General Meeting of the British Association for Psychopharmacology. Cambridge, England. July 15-18,1990 1990"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0002|cit2","unstructured":"McLaren S Cookson JC Silverstone JT Bromperidol decanoate: a comparative study in chronic schizophrenia 8th World Congress of Psychiatry; Athens, Greece"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0003|cit3","first-page":"67","article-title":"Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates","volume":"7","author":"McLaren","year":"1992","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0004|cit4","unstructured":"Casacchia M Di Michele V Volonte MV Rossi A Bromperidol decanoate versus fluphenazine decanoate in schizophrenia 8th World Congress of Psychiatry. Athens, Greece"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0005|cit5","first-page":"1379","article-title":"Therapeutic evaluation of bromperidol decanoate in schizophrenia - a double-blind comparison vs. fluphenazine decanoate","volume":"114","author":"Rossi","year":"1990","journal-title":"Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0006|cit6","first-page":"265","article-title":"Action of bromperidol decanoate in the treatment of negative symptoms of schizophrenia - comparison with haloperidol decanoate","volume":"27","author":"Rossi","year":"1992","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0007|cit7","unstructured":"Bellini L Smeraldi E Virzi A Aguglia E Bromperidol decanoate versus placebo in residual schizophrenia 8th World Congress of Psychiatry. Athens, Greece"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0008|cit8","first-page":"187","article-title":"Bromperidol decanoate versus placebo in treating schizophrenia in the residual phase","volume":"6","author":"Smeraldi","year":"1990","journal-title":"New Trends in Experimental and Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001719.pub4-BIB0009|cit9","first-page":"271","article-title":"Efficacia terapeutica e tollerabilita del bromperidolo decanoato in pazienti psicotici gia in trattamento con aloperidolo o clorpromazina","volume":"27","author":"Bernardi","year":"1992","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0010|cit10","unstructured":"Boeykens DHJ Tan BK Nuijten S 6-month study of bromperidol decanoate in chronic psychotic patients 14th CINP Congress. Florence, Italy"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-1019585","article-title":"A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients","volume":"14","author":"Brannen","year":"1981","journal-title":"Pharmacopsychiatria"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000468826","article-title":"Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research","volume":"13","author":"Bures","year":"1978","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000468454","article-title":"Clinical evaluation of bromperidol versus haloperidol in psychotic patients","volume":"15","author":"Denijs","year":"1980","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0014|cit14","first-page":"267","article-title":"Clinical evaluation of sultopride hydrochloride on outpatients with schizophrenia","volume":"23","author":"Fukahori","year":"1995","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0015|cit15","first-page":"233","article-title":"Clinical therapeutic experience with bromperidol - a double blind and open study","volume":"25","author":"Germana","year":"1990","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0016|cit16","unstructured":"Gould S Sethna E Burns B Kanakaratnam G Leslie N Goodhead D Moss M Watt JS Maintenance therapy of schizophrenia with a novel depot neuroleptic bromperidol decanoate 3rd World Congress of Biological Psychiatry. Stockholm, Sweden"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0017|cit17","unstructured":"Gould S El Sobky A El Assra A Hajioff J Blain P Wiles D Relationship between plasma drug concentrations and clinical response after treatment with bromperidol or fluphenazine decanoate 13th CINP Congress. Jerusalem, Israel"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000468827","article-title":"The use of bromperidol in an open study","volume":"13","author":"Hucker","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub4-BIB0019|cit19","first-page":"1296","article-title":"The clinical psychopharmacological efficacy of bromperidol for schizophrenia comparison with haloperidol by the single-blind cross-over method","volume":"21","author":"Hyugano","year":"1986","journal-title":"Shinryo to Shinyaku"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0020|cit20","first-page":"120","article-title":"A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique","volume":"21","author":"Itoh","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000468825","article-title":"Neuroleptic potency of bromperidol","volume":"13","author":"Kaumeier","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0022|cit22","first-page":"296","article-title":"The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double-blind method","volume":"12","author":"Kodama","year":"1984","journal-title":"Igaku to Yakugaku"},{"issue":"11","key":"10.1002\/14651858.CD001719.pub4-BIB0023|cit23","first-page":"3721","article-title":"The comparative study of bromperidol and clocapramine for schizophrenia by the double-blind method","volume":"61","author":"Kokasa","year":"1984","journal-title":"Rinsho To Kenkyu"},{"issue":"10","key":"10.1002\/14651858.CD001719.pub4-BIB0024|cit24","first-page":"1283","article-title":"A double blind comparison of bromperidol and clocapramine on schizophrenia","volume":"13","author":"Kudo","year":"1984","journal-title":"Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0025|cit25","first-page":"51","article-title":"Valutazione dell'efficacia e della tollerabilita del trattamento a lungo termine con bromperidolo decanoato nei disturbi psicotici","volume":"33","author":"Levi Minzi","year":"1992","journal-title":"Minerva Psichiatrica"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0026|cit26","first-page":"147","article-title":"Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients","volume":"78","author":"Malfroid","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0027|cit27","first-page":"187","article-title":"Schizophrenic disorder in active phase: Double-blind study between bromperidol and haloperidol","volume":"16","author":"Mauri","year":"1994","journal-title":"Giornale di Neuropsicofarmacologia"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/1096-8628(20000612)96:3<422::AID-AJMG35>3.0.CO;2-5","article-title":"No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study","volume":"96","author":"Mihara","year":"2000","journal-title":"American Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-1781(00)00247-X","article-title":"No relationship between - 141 C Ins\/del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonist in schizophrenic patients: a preliminary study","volume":"1","author":"Mihara","year":"2001","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-244X-8-95","article-title":"The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)","volume":"8","author":"Hanssens","year":"2008","journal-title":"BMC psychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0031|cit31","unstructured":"Millet B A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients (Schizophrenia Trial of Aripiprazole - STAR) http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0032|cit32","first-page":"373-82. Awaits","article-title":"Clinical effects of bromperidol on schizophrenia","volume":"30","author":"Nishizono","year":"1984","journal-title":"Kyushu Shinkei Seishin Igaku Kyushu Neuro-psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub4-BIB0033|cit33","first-page":"3349","article-title":"The double-blind comparative study of bromperidol and haloperidol in the treatment of schizophrenic inpatients","volume":"18","author":"Onodera","year":"1984","journal-title":"Kiso to Rinsho"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00007691-199704000-00008","article-title":"No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite","volume":"19","author":"Otani","year":"1997","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0035|cit35","first-page":"1","article-title":"Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation","volume":"34","author":"Parent","year":"1983","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0037|cit36","first-page":"96","article-title":"Clinical experiences in an open and a double-blind trial","volume":"78","author":"Poldinger","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0036|cit37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000468306","article-title":"Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol","volume":"12","author":"Poldinger","year":"1977","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0038|cit38","first-page":"1089","article-title":"Therapeutic evaluation of bromperidol in schizophrenia - double-blind comparison with chlorpromazine in chronic patients and open administration in schizophrenics with acute symptomatology","volume":"36","author":"Psaras","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"suppl1","key":"10.1002\/14651858.CD001719.pub4-BIB0039|cit39","first-page":"159","article-title":"Comparison of risperidone and dopamine selective inhibitors in acutely exacerbated schizophrenic patients","volume":"11","author":"Saito","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0040|cit40","first-page":"38","article-title":"Clinical study comparing 2 different therapeutic regimens (morning vs evening administration) of bromperidol in the treatment of schizophrenia","volume":"15","author":"Scapicchio","year":"1993","journal-title":"Giornale di Neuropsicofarmacologia"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0041|cit41","first-page":"39","article-title":"Bromperidol decanoate in the residual phase of schizophrenia","volume":"37","author":"Smeraldi","year":"1996","journal-title":"Minerva Psichiatrica"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0042|cit42","first-page":"67","article-title":"A double-blind comparative study of bromperidol versus haloperidol in schizophrenic patients","volume":"8","author":"Spina","year":"1992","journal-title":"New Trends in Experimental and Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0043|cit43","unstructured":"Suarez Richards M Lopez Romera A Amoretti T Follow-up of nine schizophrenic patients treated during 52 weeks with bromperidol decanoate 14th CINP Congress. Florence, Italy"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199706000-00003","article-title":"Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine","volume":"19","author":"Suzuki","year":"1997","journal-title":"Theraputic Drug Monitoring"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0046|cit45","first-page":"155","article-title":"Effects and side-effects of bromperidol in comparison with other antipsychotic drugs","volume":"78","author":"Woggon","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000468337","article-title":"Double-blind comparison of bromperidol and perphenazine","volume":"13","author":"Woggon","year":"1978","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0047|cit47","first-page":"236","article-title":"A single-blind comparison of bromperidol and sulpiride in hospitalized schizophrenics","volume":"93","author":"Yamagami","year":"1993","journal-title":"Acta Psychiatrica Belgica"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub4-BIB0048|cit48","first-page":"4-5, 27","article-title":"Health education of families of schizophrenic patients: the impact of emotional disorder [translated by Google Translate]","volume":"7","author":"Zhao","year":"2008","journal-title":"Modern Clinical Nursing"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"Aaes-Jorgensen A Pharmacokinetics of oral and depot neuroleptics - clinical relevance Symposium Espo. Feb 1, 1985 1985","DOI":"10.1007\/978-1-4613-2363-1_112"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001718.pub2","article-title":"Depot fluspirilene for schizophrenia","author":"Abhijnhan","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0054|cit54","volume-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"issue":"6","key":"10.1002\/14651858.CD001719.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","article-title":"Long term depot antipsychotics. A risk benefit assessment","volume":"10","author":"Barnes","year":"1994","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub4-BIB0058|cit58","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0059|cit59","volume-title":"Cochrane Reviewers' Handbook 4.20 [updated March 2003, available in Cochrane Library]","author":"Clarke","year":"2003"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0060|cit60","volume-title":"The Neuropsychology of Schizophrenia","author":"David","year":"1994"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000307","article-title":"Depot fluphenazine decanoate and enanthate for schizophrenia","author":"David","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","article-title":"Depot antipsychotic drugs. Place in therapy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0063|cit63","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1192\/bjp.195.52.s29","article-title":"Second-generation antipsychotic long-acting injections: systematic review","volume":"52","author":"Fleischhacker","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0071|cit71","first-page":"124","article-title":"ECDEU Assessment manual for psychopharmacology","volume-title":"DHEW publication No (ADM)","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.euroneuro.2010.01.001","article-title":"How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?","volume":"20","author":"Hamann","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001719.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4088\/JCP.v67n1216","article-title":"Attitudes of psychiatrists toward antipsychotic depot medication","volume":"67","author":"Heres","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0077|cit77","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD001719.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0920-9964(97)85354-6","article-title":"The 100-year epidemiology of schizophrenia","volume":"28","author":"Jablensky","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/19.2.287","article-title":"Psychopharmacologic treatment of schizophrenia","volume":"19","author":"Kane","year":"1993","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia","volume":"8","author":"Kane","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0081|cit81","article-title":"Positive and negative syndrome scale (PANSS) manual","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD001719.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1-3","key":"10.1002\/14651858.CD001719.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the Quality of Reports Parallel-Group Randomized Trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10","key":"10.1002\/14651858.CD001719.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD001719.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD001719.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0895-4356(94)00141-C","article-title":"Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs","volume":"48","author":"Simon","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub4-BIB0096|cit96","first-page":"177","article-title":"Conversion of bromperidol to reduced bromperidol in human liver","volume":"5","author":"Someya","year":"1991","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.ps.56.3.283","article-title":"Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice","volume":"56","author":"West","year":"2005","journal-title":"Psychiatric Services"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub4-BIB0100|cit100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001719","article-title":"Depot bromperidol decanoate for schizophrenia","author":"Adams","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001719.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T19:55:14Z","timestamp":1725479714000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001719.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,11,14]]},"references-count":100,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001719.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,14]]}}}